Pharmacokinetics and excretion of (14)C-omacetaxine in patients with advanced solid tumors

Background Omacetaxine mepesuccinate is indicated in adults with chronic myeloid leukemia resistant and/or intolerant to ≥ 2 tyrosine kinase inhibitor treatments. This phase I study assessed the disposition, elimination, and safety of (14)C-omacetaxine in patients with solid tumors. Methods The stud...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Invest New Drugs
Auteurs principaux: Nijenhuis, Cynthia M., Hellriegel, Edward, Beijnen, Jos H., Hershock, Diane, Huitema, Alwin D. R., Lucas, Luc, Mergui-Roelvink, Marja, Munteanu, Mihaela, Rabinovich-Guilatt, Laura, Robertson, Philmore, Rosing, Hilde, Spiegelstein, Ofer, Schellens, Jan H. M.
Format: Artigo
Langue:Inglês
Publié: Springer US 2016
Sujets:
Phase I Studies
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5007276/
https://ncbi.nlm.nih.gov/pubmed/27221729
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-016-0360-9
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires